Clinical Trials Logo

Grass Pollen Allergy clinical trials

View clinical trials related to Grass Pollen Allergy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04435678 Completed - Clinical trials for House Dust Mite Allergy

Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens

MADMAX
Start date: July 22, 2020
Phase: N/A
Study type: Interventional

About 20% of the general population are affected by an allergy - with an upward trend. Quite often, allergic people do not consider their disease as serious and suffer from subsequent complications, like allergic asthma, later in their life. The sooner the allergen source is identified, the sooner the therapeutic intervention (e.g. dietary recommendations, allergen avoidance, anti-inflammatory treatment or allergen immunotherapy) can be started. Cross-reactivity may also play an important role. Therefore, a comprehensive allergy test is essential for an optimal treatment of patients. Modern multiplex testing is an individualized diagnostic approach, which may help to identify eligible patients for allergen immunotherapy and may identify risk groups by analyzing the sIgE profile. Until now, published data on the clinical usability of multiplex allergy diagnostic test systems are often limited. Even though, available studies show a good correlation between conventionally used multiplex or singleplex assays (ISAC or ImmunoCAP) and the new multiplex assay (ALEX and ALEX²), the results are often based on small sample sizes investigating many different allergens. Therefore, this clinical performance study is conducted to evaluate the diagnostic accuracy of the ALEX² IgE multiplex test using the Multi Array Explorer (MAX 45k, MacroArray Diagnostics) automated laboratory system in comparison to a conventional IgE singleplex test system as well as clinical symptoms and skin prick test results in a total of 826 patients. Patients with the most common inhalant allergies (e.g. grass pollen, house dust mite or cat allergy) will be included as well as patients suffering from Hymenoptera venom allergy, which is the major cause of anaphylaxis.

NCT ID: NCT01830673 Completed - Clinical trials for Grass Pollen Allergy

Regulatory T-cells After Subcutaneous Immunotherapy

RTCAS
Start date: October 2011
Phase: N/A
Study type: Observational

The primary endpoint was the induction of T-regulatory cells under s specific subcutaneous immunotherapy (SCIT). Patients suffering from grass pollen allergy (relevant clinical symptomes during the pollen season, Skin Prick test diamter >4mm or RAST class II or higher) were included. The patients were allocated to three study groups: Group 1: during and directly after SCIT (after completion the 2nd or 3rd year of treatment) Group 2: completed SCIT more then three years ago Group 3: Patients with clinically relevant grass pollen allergy without SCIT. The investigators analyzed the lung function parameters, exhaled NO (eNO) and asked the patients to record symptoms during the adjacent pollen season. A blood sample was drawn to analyze the amount of TH1 and TH2 and regulatory T-cells, inflammatory markers(IL-2, IL-5, IL-10, IL-12/23, TNF-alpha, IFN-gamma) and blocking antibodies (IgG, IgG4).

NCT ID: NCT01538979 Completed - Clinical trials for Grass Pollen Allergy

Phase II Study of Grass Pollen Allergy Vaccine BM32

Start date: March 2012
Phase: Phase 2
Study type: Interventional

The study will evaluate the efficacy and safety of BM32 in grass pollen allergic subjects. It will test the hypothesis that either of two doses of BM32 will lead to a sustained relief off allergy symptoms over a two year study period.

NCT ID: NCT01445002 Completed - Clinical trials for Grass Pollen Allergy

Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy

Start date: October 2011
Phase: Phase 2
Study type: Interventional

The study will evaluate the dose response of immunotherapy against grass pollen allergy using the recombinant grass pollen vaccine BM32. Efficacy will be analyzed by: - skin prick testing - grass pollen inhalation challenge - antibody responses. In addition, the safety of subcutaneous application of BM32 will be evaluated.

NCT ID: NCT01308021 Completed - Hay Fever Clinical Trials

Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis

Start date: December 2010
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of grass pollen-derived peptides administrated orally to treat seasonal allergic rhinoconjunctivitis.

NCT ID: NCT00773240 Completed - Clinical trials for Grass Pollen Allergy

A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment

Start date: April 2008
Phase: Phase 3
Study type: Interventional

The study assess the pharmacodynamic effect and the tolerability of Grazax treatment initiated in the grass pollen season in subjects with seasonal grass pollen induced rhinoconjunctivitis

NCT ID: NCT00264459 Completed - Clinical trials for Grass Pollen Allergy

Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture

Start date: February 2003
Phase: Phase 3
Study type: Interventional

The trial is performed to asses efficacy and safety of a sublingual extract of a six grass pollen mixture

NCT ID: NCT00263601 Completed - Clinical trials for Grass Pollen Allergy

Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis

Start date: November 2001
Phase: Phase 3
Study type: Interventional

The trial is performed to assess efficacy and safety of the Grass Pollen Allergoid in Allergic Rhinoconjunctivitis